What’s the current market cap for Sarepta Therapeutics stock?

Sarepta Therapeutics (SRPT) has a market cap of $1.7bn as of June 16, 2026.

What is the P/E ratio for Sarepta Therapeutics stock?

The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 24.73 as of June 16, 2026.

Does Sarepta Therapeutics stock pay dividends?

No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Sarepta Therapeutics dividend payment date?

Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.

What is the beta indicator for Sarepta Therapeutics?

Sarepta Therapeutics (SRPT) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Sarepta Therapeutics stock | $SRPT Share Price

13:30

15:10

16:45

18:25

20:00

About Sarepta Therapeutics

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Ticker

$SRPT

Sector

Health

Primary listing

NASDAQ

Employees

835

Headquarters

Cambridge, United States

Website

www.sarepta.com

SRPT Metrics

BasicAdvanced

$1.7bn

24.73

$0.64

0.21

What the Analysts think about SRPT

Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.

Bulls say / Bears say

Sarepta reported non-GAAP EPS of $3.16 in Q1 2026, beating expectations by 219% and reversing a GAAP operating loss of $300 million in Q1 2025 to achieve $358 million in operating income.

Collaboration and other revenue rose to $400 million in Q1 2026, driven by a $325 million milestone from Roche option expiry and a $40 million milestone for the first commercial Elevidys sale in Japan.

The company delivered positive operating cash flow and had $748 million in cash and investments at the end of Q1 2026, giving it enough resources to fund all its pipeline programs without external financing.

The FDA added a boxed warning to Elevidys in November 2025, limiting its use to ambulatory Duchenne muscular dystrophy patients aged four and older after two patient deaths from liver failure, severely narrowing its addressable market.

Elevidys net product revenue declined to $102 million in Q1 2026 from $110 million in Q4 2025, signaling persistent commercial challenges and slower uptake due to safety label changes.

Core product revenues dropped 46% year-over-year in Q1 2026 to $331 million, highlighting the weakness in Sarepta’s PMO franchise as competition and labeling limits take a toll.

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

SRPT Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

SRPT Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SRPT

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Sarepta reported non-GAAP EPS of $3.16 in Q1 2026, beating expectations by 219% and reversing a GAAP operating loss of $300 million in Q1 2025 to achieve $358 million in operating income.

Elevidys net product revenue declined to $102 million in Q1 2026 from $110 million in Q4 2025, signaling persistent commercial challenges and slower uptake due to safety label changes.

Core product revenues dropped 46% year-over-year in Q1 2026 to $331 million, highlighting the weakness in Sarepta’s PMO franchise as competition and labeling limits take a toll.

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.